Handelsbanken Fonder AB Sells 52,327 Shares of IQVIA Holdings Inc. $IQV

Handelsbanken Fonder AB lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 28.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 131,989 shares of the medical research company’s stock after selling 52,327 shares during the period. Handelsbanken Fonder AB’s holdings in IQVIA were worth $25,070,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Versant Capital Management Inc boosted its holdings in shares of IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after buying an additional 53 shares during the last quarter. CVA Family Office LLC grew its position in shares of IQVIA by 11.6% during the 3rd quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock valued at $124,000 after acquiring an additional 68 shares during the period. UMB Bank n.a. increased its stake in shares of IQVIA by 11.0% during the 3rd quarter. UMB Bank n.a. now owns 749 shares of the medical research company’s stock worth $142,000 after purchasing an additional 74 shares during the last quarter. E Fund Management Co. Ltd. raised its holdings in shares of IQVIA by 3.7% in the 2nd quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after purchasing an additional 74 shares during the period. Finally, Hartford Investment Management Co. lifted its stake in IQVIA by 0.8% in the third quarter. Hartford Investment Management Co. now owns 9,964 shares of the medical research company’s stock valued at $1,893,000 after purchasing an additional 77 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on IQV shares. BMO Capital Markets set a $250.00 target price on IQVIA in a research note on Friday, February 6th. Citigroup lowered their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. UBS Group cut their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Truist Financial dropped their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Finally, Evercore reiterated an “outperform” rating and issued a $225.00 price objective on shares of IQVIA in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $231.80.

IQVIA Stock Performance

IQVIA stock opened at $179.09 on Friday. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The firm has a market capitalization of $30.39 billion, a PE ratio of 22.79, a price-to-earnings-growth ratio of 1.72 and a beta of 1.37. The firm’s 50 day simple moving average is $212.19 and its 200 day simple moving average is $208.00.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.